NCT00626535View on ClinicalTrials.gov

A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD)

PHASE3CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

February 29, 2004

Study Completion Date

February 29, 2004

Conditions
Symptomatic Gastroesophageal Reflux Disease (sGERD)
Interventions
DRUG

Esomeprazole

20mg Oral Once Daily

DRUG

Matching placebo

Oral Once Daily

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT00626535 - A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD) | Biotech Hunter | Biotech Hunter